Affiliation:
1. The Kuban State Medical University
Abstract
Non-alcoholic fatty liver disease (NAFLD) is widespread in the population and is the leading cause of cirrhosis and hepatocellular carcinoma. NAFLD includes a continuum from steatosis to non-alcoholic steatohepatitis with rapidly progressive fibrosis. NAFLD has a bidirectional relationship with components of metabolic syndrome and type 2 diabetes, increasing the risk of complications. The main causes of death in NAFLD are cardiovascular disease and extrahepatic malignancy, but advanced liver fibrosis is a key prognostic marker, and the risk of death can be assessed using a combination of non-invasive tests. There is currently no approved therapy for NAFLD, although several drugs are in advanced stages of development. An analysis of clinical studies, their meta-analyzes and literature reviews from the PubMed and MEDLINE databases was carried out for 18 keywords corresponding to the review topic, more than 5000 articles published in recent years were studied. The current understanding of epidemiology, natural history, pathogenesis, diagnosis, risk assessment, prevention and treatment of NAFLD is summarized.
Publisher
Rostov State Medical University
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献